NEW YORK (GenomeWeb News) – BiOasis Technologies and the University of British Columbia will collaborate to develop and test a biomarker assay for Alzheimer's disease, the company said today.

The goal of the collaboration is to develop and test concentration levels of the p97 protein in blood using an enzyme-linked immunosorbent assay test to diagnose Alzheimer's. The firms said that the "quick and accurate" test would help doctors diagnose the disease and monitor the effectiveness of therapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.